Utah Doc Banned from Prescribing Pills After License Surrender
Published Date: 7/22/2025
Notice
Summary
Dr. Thomas Draschil from Utah lost his DEA registration because he gave up his state medical and controlled substance licenses last year. Since he didn’t ask for a hearing, the DEA officially canceled his right to handle controlled substances starting July 22, 2025. This means he can no longer legally prescribe or manage controlled drugs, affecting his medical practice and any related income.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Dr. Draschil
Dr. Thomas Draschil's DEA Certificate of Registration No. FD9980118 is revoked and the Order is effective August 21, 2025. Because his Utah physician license and Utah controlled-substance license were voluntarily surrendered on July 29, 2024, he is not authorized to handle, prescribe, dispense, or administer controlled substances in Utah.
Pending Renewal and New Registrations Denied
The DEA denied any pending applications by Thomas Draschil to renew or modify his registration and denied any pending application for additional registration in Utah, with that denial effective August 21, 2025. The Order follows findings that he is not licensed as a practitioner in Utah.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-13712, Notice of Request for Revision to and Extension of Approval of an Information Collection; Federal Plant Pest and Noxious Weed Regulations
The Animal and Plant Health Inspection Service wants to update and keep approval for a form that helps control harmful plant pests and noxious weeds. This affects farmers, gardeners, and businesses dealing with plants, making sure they follow the rules to keep plants safe. They’re asking for more time to collect this info, with no new costs expected, so everyone can keep protecting our green spaces.
Next: 2025-13716, Proposed Collection; Comment Request; Extension: Form 18-K-Annual Report
The SEC wants to keep using Form 18-K, an annual report that foreign governments with U.S. securities must file. About 37 groups spend around 8 hours each year filling it out, with no extra costs involved. The SEC is asking for public comments by September 22, 2025, to make sure this form stays useful and easy to handle.